Carlyle and SK Capital to take gene therapy firm bluebird bio private
The Carlyle Group and SK Capital Partners have agreed to acquire bluebird bio, Inc, a Somerville, Massachusetts-based gene therapy firm, in a take-private deal. According to terms of the agreement, bluebird stockholders will receive $3 per share in cash.
The Carlyle Group (NASDAQ:CG – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
(Reuters) - U.S.-based investment firm Carlyle Group has entered India's auto components market by buying a controlling stake ...
AlpInvest Secondaries Fund VIII has raised nearly $9.4 billion as of 31 December 2024, according to materials prepared for ...
Bank of America Securities analyst Craig Siegenthaler maintained a Sell rating on Carlyle Group (CG – Research Report) yesterday and set a ...
Carlyle Group Inc. completed its acquisition of a controlling stake in an Indian auto-parts making platform formed by the ...
The Carlyle Group has announced the listing of its portfolio company Hexaware Technologies, a global IT services company, on the Bombay Stock Exchange and National Stock Exchange in India. The total ...
Readers hoping to buy The Carlyle Group Inc. ( NASDAQ:CG ) for its dividend will need to make their move shortly, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback